Clinical trials: Cyclophosphamide, completed
Multiple Myeloma
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of cilta-cel out-of-specification (OOS).
- Trial name
- NCT05347485
- Testing
- Cilta-cel, Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)
- Where
- 18 sites in United States
- Volunteers
- 86 people
- Sponsor
- Janssen Scientific Affairs, LLC
Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
This clinical trial studies the use of reduced intensity chemotherapy and radiation therapy before donor stem cell transplant in treating patients with hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Aplastic Anemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT02566304
- Testing
- Fludarabine, Total-Body Irradiation, T Cell-Depleted Donor Lymphocyte Infusion
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Follicular Lymphoma
A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients
The purpose of this study is to determine whether R-FC is more beneficial that R-CVP in the treatment of older patients (aged 60 or over) with Follicular Lymphoma (FL).
- Trial name
- PACIFICO (NCT01303887)
- Testing
- Rituximab, Cyclophosphamide, Vincristine
- Where
- 73 sites in United Kingdom
- Volunteers
- 680 people
- Sponsor
- University of Liverpool
Breast Cancer
ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer
Trial for the optimization of risk assessment and therapy success prediction in patients with early breast cancer by the use of biomarkers in advance to therapy decision-making to personalize therapies.
- Trial name
- ADAPT (NCT01779206)
- Testing
- Epirubicin, Cyclophosphamide, Docetaxel
- Where
- 2 sites in Germany
- Volunteers
- 4,936 people
- Sponsor
- Women's Cancer Study Group GmbH
Cardiotoxicity, Cardiovascular Disease
Effect of Anthracyclines and Cyclophosphamide on Cardiovascular Responses
The present study aims to investigate the chronic effect of treatment with doxorubicin and cyclophosphamide on neurovascular control and blood pressure in women undergoing adjuvant treatment for breast cancer.
- Conditions
- Cardiotoxicity, Cardiovascular Disease, Neurovascular Disorder, Endothelial Disfunction
- Trial name
- NCT04568161
- Testing
- Physical Characteristics, Muscular Sympathetic Nervous Activity, Cardiac Function
- Where
- Brazil
- Volunteers
- 15 people
- Sponsor
- University of Sao Paulo General Hospital
Leukemia, Mucositis
Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Leukemia, Mucositis, Oral Complications
- Trial name
- UKALL14 (NCT01085617)
- Testing
- palifermin, rituximab, cyclophosphamide
- Sponsor
- University College, London
Multiple Myeloma
Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma
The present study is a multicenter, prospective phase II-study to evaluate the chronic GvHD and progression-free survival at 2 years after after allogeneic stem cell transplantation for patients with multiple myeloma.
- Trial name
- NCT03700450
- Testing
- Cyclophosphamide
- Where
- 3 sites in Germany
- Volunteers
- 37 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma
Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting
We hope to demonstrate that YESCARTA can be safely administered in the outpatient setting if we closely monitor subjects with physical exams, wearable devices, and telemedicine visits and only admit those who meet specified…
- Trial name
- NCT05108805
- Testing
- Telemedicine Visit, Vital sign measurements, Out-Patient Clinic Visit
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
ANCA-Associated Vasculitis
A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
The primary objective is to evaluate the efficacy of CCX168 (avacopan) to induce and sustain remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with…
- Trial name
- ADVOCATE (NCT02994927)
- Testing
- Avacopan, Prednisone, Cyclophosphamide
- Where
- 198 sites in United States, Australia and 18 more
- Volunteers
- 331 people
- Sponsor
- Amgen
Cyclophosphamide Toxicity, Allogenic Haematopoetic Transplantation
Influence of Timing PTCy in AlloSCT
Cyclophosphamide, administered after the infusion of haematopoietic progenitor cells, is used to prevent graft-versus-recipient disease (GVHD) in patients undergoing allogeneic haematopoietic stem cell transplantation (allogeneic…
- Trial name
- NCT05886335
- Testing
- Cyclophosphamide
- Where
- Spain
- Volunteers
- 180 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
ANCA-associated Vasculitis
Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis
The aim of this trial is to test the safety and efficacy of two dose regimens of the complement C5a receptor CCX168 in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
- Trial name
- NCT02222155
- Testing
- CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids, CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids
- Where
- 43 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Amgen
Metastatic Melanoma
Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma
In this randomized controlled phase III study the investigators will evaluate whether TIL infusion preceded by non-myeloablative chemotherapy and followed by high dose bolus interleukin-2 can result in an improved progression…
- Trial name
- TIL (NCT02278887)
- Testing
- Translational research, Cyclophosphamide, Fludarabine
- Where
- 2 sites in Denmark, Netherlands
- Volunteers
- 168 people
- Sponsor
- The Netherlands Cancer Institute
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic disease.
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Burkitt Lymphoma
- Trial name
- NCT00719888
- Testing
- Cyclophosphamide, Cyclosporine, Double-Unit Umbilical Cord Blood Transplantation
- Where
- 3 sites in United States
- Volunteers
- 135 people
- Sponsor
- Fred Hutchinson Cancer Center
AL Amyloidosis
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
AL amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down.
- Trial name
- NCT04304144
- Testing
- CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Pemphigus Vulgaris
Comparing DCP and DAP for Pemphigus Vulgaris
What's the study about? This study focused on comparing two different treatments for pemphigus vulgaris, a skin condition caused when body's immune system works against itself.
- Trial name
- DCP;DAP (NCT06846255)
- Testing
- Dexamethasone Cyclophosphamide Pulse therapy, Dexamethasone Azathioprine Pulse therapy
- Where
- Pakistan
- Volunteers
- 66 people
- Sponsor
- Jinnah Postgraduate Medical Centre
Early Primary Breast Cancer
A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response
Comparison of pre-surgical Myocet/ Cyclophosphamide (MC) q3w followed by either MC or Paclitaxel - depending on early response assessment by ultrasound or by toxicity for elderly non frail primary breast cancer patients with…
- Trial name
- NCT02214381
- Testing
- Myocet, Cyclophosphamide, Paclitaxel
- Where
- 2 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Women's Cancer Study Group GmbH
Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
This pilot phase II trial studies the side effects of azacitidine and combination chemotherapy in infants with acute lymphoblastic leukemia and KMT2A gene rearrangement.
- Conditions
- Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- NCT02828358
- Testing
- Azacitidine, Biospecimen Collection, Computed Tomography
- Where
- 170 sites in United States, Australia and 2 more
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)
This study enrolls patients who have a type of cancer that arises from the liver called hepatocellular carcinoma. The cancer has come back, has not gone away after standard treatment, has spread outside of the liver or the…
- Trial name
- GLYCAR (NCT02905188)
- Testing
- GLYCAR T cells, Cytoxan, Fludarabine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Baylor College of Medicine
Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
This phase II trial studies how well combination chemotherapy and dasatinib works in treating participants with Philadelphia-positive or B-cell receptor-ABL positive acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive
- Trial name
- NCT00390793
- Testing
- Cyclophosphamide, Cytarabine, Dasatinib
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- M.D. Anderson Cancer Center
Neuroblastoma
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
This study will combine an oral drug called DFMO with celecoxib (also oral) and two IV chemotherapy medicines called cyclophosphamide and topotecan.
- Trial name
- DFMO (NCT02030964)
- Testing
- DFMO, Celecoxib, Cyclophosphamide
- Where
- 13 sites in United States, Australia and 1 more
- Volunteers
- 30 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium